WebNews
Please enter a web search for web results.
NewsWeb
Pfizer delays patent cliff for blockbuster heart drug
12+ hour, 42+ min ago (41+ words) Endpoints News Pfiz'er de'lays patent cliff for block'buster heart drug Pfiz'er is staving off Vyn'damax com'pe'ti'tion for an'oth'er two years. Think we're worth reading - tell Google. Confirm Endpoints as a trusted biopharma news source...
Be One joins the VEGF competition, but with a trispecific antibody
15+ hour, 36+ min ago (59+ words) Endpoints News Be One joins the VEGF com'pe'ti'tion, but with a trispe'cif'ic an'ti'body The phar'ma com'pa'ny for'mer'ly known as Bei Gene has plucked an ex'per'i'men'tal can'cer drug from a Chi'nese biotech, aim'ing to go broad'er than its com'peti'tors. Think we're…...
FDA claims trial 'manipulation' tainted approval of Chemo Centryx drug now owned by Amgen
17+ hour, 9+ min ago (67+ words) Endpoints News FDA claims tri'al 'ma'nip'u'la'tion' taint'ed ap'proval of Chemo'Cen'tryx drug now owned by Am'gen The FDA ac'cused Chemo'Cen'tryx of ma'nip'u'lat'ing the re'sults of a piv'otal clin'i'cal tri'al used to ap'prove the drug Tavneos, es'ca'lat'ing the agency's ef'fort to pull…...
Lilly strikes second partnership this year for recombinase-based gene editing
19+ hour, 18+ min ago (62+ words) Endpoints News Lil'ly strikes sec'ond part'ner'ship this year for re'com'bi'nase-based gene edit'ing Decades be'fore CRISPR gene edit'ing was in'vent'ed, sci'en'tists tried to ma'nip'u'late genes with en'zymes called re'com'bi'nas'es. The pro'teins were pre'cise but proved tricky to use " Think we're worth…...
Novartis CEO disheartened by Germany's planned "60 B cuts to healthcare spending
19+ hour, 43+ min ago (65+ words) Endpoints News No'var'tis CEO dis'heart'ened by Ger'many's planned "60 B cuts to health'care spend'ing No'var'tis CEO Vas Narasimhan said the Swiss com'pa'ny is "very dis'ap'point'ed" by Ger'many's plan to shave off more than "60 bil'lion in health'care costs that " Think we're worth…...
Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what's next
1+ day, 14+ hour ago (66+ words) Endpoints News Q&A: In'tel'lia CEO talks first Phase 3 CRISPR read'out and what's next In'tel'lia Ther'a'peu'tics re'port'ed this morn'ing on the Phase 3 suc'cess of a gene edit'ing treat'ment for hered'i'tary an'gioede'ma, a dis'ease that caus'es un'pre'dictable, dis'fig'ur'ing and " Think we're worth…...
Revolution Medicines threatens to sue Erasca in showdown over closely watched RAS drugs
1+ day, 12+ hour ago (52+ words) Endpoints News Rev'o'lu'tion Med'i'cines threat'ens to sue Eras'ca in show'down over close'ly watched RAS drugs Ear'li'er this month, a new can'cer drug cap'ti'vat'ed pa'tients and in'vestors. Now the lawyers get their turn. On Mon'day, the biotech Eras'ca said it had…...
Thermo Fisher sells microbiology biz; Ligand to buy XOMA
1+ day, 15+ hour ago (55+ words) Endpoints News Ther'mo Fish'er sells mi'cro'bi'ol'o'gy biz; Lig'and to buy XO'MA Ther'mo Fish'er Sci'en'tif'ic sells mi'cro'bi'ol'o'gy busi'ness: As'torg, a Eu'ro'pean pri'vate eq'ui'ty firm, will ac'quire the unit for $1. 075 bil'lion. Ther'mo Fish'er's " Think we're worth reading - tell Google. Confirm Endpoints as…...
Global partnering before the term sheet: de-risking biopharma deals from day one
1+ day, 20+ hour ago (315+ words) As de'vel'op'ment pro'grams be'come more com'plex and glob'al from ear'li'er stages, this re'al'i'ty is be'com'ing in'creas'ing'ly ev'i'dent. Suc'cess'ful part'ner'ships to'day are less about ne'go'ti'at'ing the "per'fect" deal and more about align'ing ear'ly on how that deal will ac'tu'al'ly be ex'e'cut'ed....
Updated: Compass Therapeutics' stock plummets as it unveils more data from pivotal biliary tract cancer trial
1+ day, 18+ hour ago (65+ words) Compass Therapeutics unveils more data from pivotal biliary tract cancer trial'Endpoints News Up'dat'ed: Com'pass Ther'a'peu'tic's' stock plum'mets as it un'veils more da'ta from piv'otal bil'iary tract can'cer tri'al A year af'ter it re'port'ed a Phase 2/3 suc'cess, Com'pass Ther'a'peu'tics on Mon'day…...